Added to YB: 2025-07-22
Pitch date: 2025-07-20
ICCC [bullish]
ImmuCell Corporation
Author Info
Kreuzmann Investing is looking for the best opportunities in Small and Microcap companies around the world. Sign up for the newsletter.
Company Info
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally.
Market Cap
$74.7M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
12.68
P/E
-120.40
EV/Sales
2.70
Sector
Biotechnology
Category
value
Growing Company with Obscure Financials, 50% Market Share and Big Optionality
ICCC: Animal health co, 52% market share in scours prevention (First Defence). Segment generates 37% EBIT margin but obscured by Mastitis (Re-Tain) awaiting FDA approval. Sales grew 16% CAGR 6yrs, capacity expanded to $30M+ after contamination issues resolved. Trading 7x fwd EV/FCF ex-hard assets ($21M facility). Mastitis approval = game-changer at 3-4x competitor pricing in $200M market. No approval = cut costs, sell facility, reveal FD earnings power. SRK Capital (terrific micro-cap investor) owns 6.4%. Upside 100-200% in few years. Risks: FDA uncertainty, distributor concentration (70% via 2 wholesalers), contamination events, milk price volatility.
Read full article (25 min)